BioMarin Pharmaceutical Inc. (BMRN) Income Statement

The reacceleration in the most recent quarter, which the data attributes in part to the Amicus transaction, suggests that inorganic contribution may be inflating the headline rate, so the organic growth rate warrants further investigation. Growth from the mature ERT franchises has been comparatively steady, while Voxzogo appears to be doing much of the incremental lifting. Investors should monitor whether the sequential gains hold once acquisition effects are fully lapped.

The Q4 2025 trough coincides with COGS rising to $295.1M, which may indicate inventory or manufacturing charges that do not repeat in the latest quarters. The recovery toward the low 80s suggests the structural premium pricing of orphan biologics remains intact, though the margin profile is still constrained by complex protein production costs. Analysts should treat the quarterly swings as noisy until a cleaner run-rate emerges.

The pattern points to negative operating leverage in recent periods, as overhead expansion outpaced gross profit growth, which may reflect integration spending and commercial build-out. Operating margin has proven highly sensitive to the SG&A line, so the path back to positive territory likely depends on whether acquisition-related overhead is absorbed. The data does not isolate one-time integration costs, so the degree of structural versus temporary deleverage remains unclear.